Silvia M. Ferrucci
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 203 publications
Eyebrow and Eyelash Outcomes During Baricitinib Treatment in Severe Alopecia Areata: A Real-World Study.
Journal: International journal of dermatology
Published: July 13, 2026
Prevalence of Regulatory Safety Risk Factors Among Adolescents and Adults With Atopic Dermatitis Receiving Advanced Systemic Therapies: An International Real-World Study.
Journal: International journal of dermatology
Published: July 02, 2026
Letter: Real-Life Improvement in Quality of Life With Delgocitinib in Chronic Hand Eczema.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: June 19, 2026
Patch test sensitization and permanent tattoos: epidemiological data from two referral centers.
Journal: European annals of allergy and clinical immunology
Published: June 10, 2026
Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis.
Real-World Effectiveness and Safety of 12 Months of Tralokinumab in Patients with Atopic Dermatitis.
Journal: Dermatology and therapy
Published: May 15, 2026
Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.
Journal: Clinical and experimental dermatology
Published: April 12, 2026
Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 11, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).
Journal: Dermatology and therapy
Published: March 17, 2026
Treatment Outcomes of Lebrikizumab after Switching from Dupilumab in Moderate-to-Severe Atopic Dermatitis involving the Head and Neck Area.
Journal: Dermatology and therapy
Published: March 11, 2026
Letter: Tralokinumab Dose Spacing in Moderate-to-Severe Atopic Dermatitis: A Real-World Case Series.
Letter: Tralokinumab Dose Spacing in Moderate-to-Severe Atopic Dermatitis: A Real-World Case Series.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: February 17, 2026
The Evolving Landscape of Contact Dermatitis Diagnosis: A Critical Appraisal of Recent Regulatory Constraints.
Journal: La Medicina del lavoro
Published: February 02, 2026
New-onset alopecia areata during calcitonin gene-related peptide inhibitor therapy: first reported case.
Journal: Dermatology reports
Published: January 31, 2026
Last Updated: 09/26/2026